Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Catalyst-rich medical technology trade: FDA 510(k) clearance on 2026-08-10, CMS NTAP reimbursement support on 2026-08-03, Q2 revenue growth of about 33% and raised full-year revenue guidance helped drive a 24% 21-day breakout.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Heavy Cash Burn ⢠Ongoing Dilution CBLL is liquid and lightly leveraged, but persistent losses, negative cash flow, dilution, and a high valuation make it a high-risk investment.
Price Behavior
Key Price Behavior Insights: ⢠Strong Uptrend ⢠Key Resistance ⢠Support Holding Support Level: $23.30â$23.50 Resistance Level: $24.80â$24.90 CBLL remains bullish after rising 31% over the last month, with $23.30â$23.50 support and a breakout above $24.80â$24.90 needed to extend gains, while a drop toward $22.90 would weaken the trend.
Sentiment & News
Key News Insights: ⢠Revenue acceleration ⢠FDA clearance ⢠Widening losses CeriBell's accelerating revenue growth, FDA-cleared platform enhancements, and expanding product pipeline support adoption momentum, though widening losses remain a key risk.
AI Summary
CBLL is an adoption-and-expansion story with attractive 92% gross margins and meaningful upside if AI-enabled seizure/delirium monitoring drives higher utilization and revenue per existing hospital, but investors should wait for evidence of narrowing losses and lower cash burn before underwriting its premium valuation.
Description
CeriBell, Inc. develops point-of-care EEG technology that uses AI to support detection and management of neurological conditions in acute care settings. Its Ceribell System pairs a bedside EEG platform with disposable headbands and portable recorders to enable rapid monitoring outside traditional neurodiagnostic labs. The company was incorporated in 2014, changed its name from Brain Stethoscope, Inc. in 2015, and is based in Sunnyvale, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 14 | Aug 21 | CBLL | CeriBell, Inc. | Catalyst-rich medical technology trade: FDA 510(k) clearance on 2026-08-10, CMS NTAP reimbursement support on 2026-08-03, Q2 revenue growth of about 33% and raised full-year revenue guidance helped drive a 24% 21-day breakout. | Closed | +3.7% |
| Dec 12 | Dec 19 | CBLL | CeriBell, Inc. | Ceribell is a hot idea fueled by recent FDA 510(k) approvals for neurological devices, strong 31% YoY revenue growth, expanding market penetration, positive technical momentum with a 27% price rise, and favorable healthcare sector dynamics supporting near-term appreciation potential. | Closed | +1.2% |